Rosetta Genomics Receives Additional U.S. Patent Protection for the Cancer Origin Test™
May 13 2015 - 09:07AM
Business Wire
Composition of matter patent protects a core
element of its diagnostic assay for the accurate identification of
the tissue of origin in cancers of unknown or uncertain primary
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and
provider of microRNA-based molecular and other diagnostics,
announces that the Company has received a Notice of Allowance from
the United States Patent and Trademark Office for U.S. patent
application No. 13/986,516 titled, “microRNAs and uses
thereof.”
The composition of matter patent claims hsa-miR-509-3p, its
complement and a sequence at least 90% identical to it, as well as
a primer and a vector comprising this microRNA. This patent
specifically covers one essential marker in the Rosetta Cancer
Origin Test™.
“We continue to make inroads building patent protection around
our microRNA technology platforms and products. This new patent
allowance further strengthens and secures the coverage for one of
our lead products, the Rosetta Cancer Origin Test™, which can
accurately identify the primary tumor type in primary and
metastatic cancer including cancer of unknown or uncertain
primary,” said Kenneth A. Berlin, President and Chief Executive
Officer of Rosetta Genomics. “Our growing intellectual property
position continues to protect and solidify our global leadership
position in microRNA biomarker technology while providing
additional revenue generating opportunities for us and enhancing
our leadership position in the commercialization of differentiated
and proprietary content in the area of personalized medicine.”
Rosetta Genomics has 42 issued patents, seven allowed patents
and 43 patents pending worldwide.
About Rosetta Cancer Testing Services
Rosetta Cancer Tests are a series of microRNA-based diagnostic
testing services offered by Rosetta Genomics. The Rosetta Cancer
Origin Test™ can accurately identify the primary tumor type in
primary and metastatic cancer including cancer of unknown or
uncertain primary (CUP). The Rosetta Lung Cancer Test™ accurately
identifies the four main subtypes of lung cancer using small
amounts of tumor cells. The Rosetta Kidney Cancer Test™ accurately
classifies the four most common kidney tumors: clear cell renal
cell carcinoma (RCC), papillary RCC, chromophobe RCC and
oncocytoma. Rosetta’s assays are designed to provide objective
diagnostic data. In the U.S. alone, Rosetta Genomics estimates that
200,000 patients a year may benefit from the Rosetta Cancer Origin
Test™, 62,000 from the Rosetta Kidney Cancer Test™ and 222,000
patients from the Rosetta Lung Cancer Test™. The Company’s assays
are offered directly by Rosetta Genomics in the U.S., and through
distributors around the world. In addition to its proprietary
products, the Company markets the Rosetta Genomics PGxOne™ and EGFR
and KRAS tests for Admera Health. With the recent acquisition of
PersonalizeDx, the company now offers a broader menu of molecular
and other assays for bladder, lung, prostate and breast cancer
patients. For more information, please visit
www.rosettagenomics.com. Parties interested in ordering any of
these tests can contact Rosetta Genomics at (215) 382-9000 ext.
309.
About Rosetta Genomics
Rosetta develops and commercializes a full range of
microRNA-based molecular diagnostics. Founded in 2000, Rosetta’s
integrative research platform combining bioinformatics and
state-of-the-art laboratory processes has led to the discovery of
hundreds of biologically validated novel human microRNAs. Building
on its strong patent position and proprietary platform
technologies, Rosetta is working on the application of these
technologies in the development and commercialization of a full
range of microRNA-based diagnostic tools. PersonalizeDx’s core
FISH, IHC and PCR-based testing capabilities and partnerships in
oncology and urology provide additional content and platforms that
complement the Rosetta offerings. Rosetta’s and PersonalizeDx’s
cancer testing services are commercially available through the
Philadelphia, PA- and Lake Forest, CA-based CAP-accredited,
CLIA-certified labs, respectively.
Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta’s future
expectations, plans and prospects, including without
limitation, statements relating to the patent protecting
a core element of Rosetta's Cancer Origin Test™, Rosetta building
patent protection around Rosetta's microRNA technology platforms
and products, Rosetta's commercial potential, and Rosetta's
intellectual property position providing additional revenue
generating opportunities,, constitute forward-looking
statements for the purposes of the safe harbor provisions under The
Private Securities Litigation Reform Act of 1995. Actual results
may differ materially from those indicated by these forward-looking
statements as a result of various important factors, including
those risks more fully discussed in the "Risk Factors" section of
Rosetta’s Annual Report on Form 20-F for the year ended December
31, 2014 as filed with the SEC. In addition, any
forward-looking statements represent Rosetta’s views only as of the
date of this release and should not be relied upon as representing
its views as of any subsequent date. Rosetta does not assume any
obligation to update any forward-looking statements unless required
by law.
Company Contacts:Rosetta GenomicsKen Berlin,
609-419-9003President &
CEOinvestors@rosettagenomics.comorInvestor Contacts:LHAAnne
Marie Fields, 212-838-3777afields@lhai.comorBruce Voss,
310-691-7100bvoss@lhai.com
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From Feb 2024 to Mar 2024
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From Mar 2023 to Mar 2024